Mizuho Maintains Buy Rating for Ventas: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Mizuho has maintained its Buy rating for Ventas (NYSE:VTR) but lowered its price target from $60.00 to $53.00. Ventas owns a diversified healthcare portfolio of over 1,200 properties across senior housing, medical office, hospital, life science, and skilled nursing/post-acute care.
May 30, 2023 | 5:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho maintains Buy rating for Ventas (NYSE:VTR) and lowers price target from $60.00 to $53.00, a potential 22.97% increase from the current share price.
Mizuho's decision to maintain a Buy rating for Ventas indicates a positive outlook for the stock. However, the lowered price target from $60.00 to $53.00 suggests a more conservative growth estimate. The potential 22.97% increase from the current share price is still significant, which is why the score is 1 (likely to go up). The relevance, importance, and confidence are high due to the direct impact of the analyst rating on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100